Topoisomerase 2α plays a pivotal role in the tumor biology of stage IV thymic neoplasia

Cancer

Volumn 109, Issue 3, 2007, Pages 502-509

  Liu, J M ^a   Wang, L S ^b,c   Huang, M H ^b,c   Hsu, W H ^b,c   Yen, S H ^b,c   Shiau, C Y ^b,c   Li, A F Y ^b,c   Tiu, C M ^b,c   Tseng, S W ^a   Huang, B S ^b,c,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anthracyclines; Her 2 neu; Thymic carcinoma; Topoisomerase 2

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; TOPOISOMERASE 2ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; CELL NUCLEUS; CHROMOSOME 17Q; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; EVALUATION; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MICROSATELLITE MARKER; ONCOGENE NEU; OVERALL SURVIVAL; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SURVIVAL TIME; T2ALPHA GENE; THYMUS CANCER; CHILD; CHROMOSOME 17; ENZYME IMMUNOASSAY; ENZYMOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROTO ONCOGENE; SURVIVAL RATE; THYMOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHROMOSOMES, HUMAN, PAIR 17; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; SURVIVAL RATE; THYMUS NEOPLASMS;

EID: 33846682699     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22404     Document Type: Article

References (44)

1. Cancer Registration system of the Department of Health of Taiwan, November 21st, 2005. Available at URL: http://crs. cph.ntu.edu.tw/crs_c/annual. html
2. Zhou R, Zettl A, Strobel P, et al. Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol. 2001;159:1853-1860.
3. Strobel P, Marx A, Zettl A, Muller-Hermelink HK. Thymoma and thymic carcinoma: an update of the WHO classification 2004. Surg Today. 2005;35:805-811.
4. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res. 2003;63:3708-3715.
5. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer. 2002;94:624-632.
6. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer. 2002;95:420-429.
7. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 2004;22:1501-1509.
8. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol. 2000;157:257-266.
9. Inoue M, Marx A, Zettl A, et al. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol. 2002;161:1507-1513.
10. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
11. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000;19:6115-6121.
12. Zhou Z, Zwelling LA, Kawakami Y, et al. Adenovirus-mediated human topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res. 1999;59:4618-4724.
13. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
14. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable Her2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
15. Loehrer PJ Sr, Perez CA, Roth LM, Greco A, Livingston RB, Einhorn LH. Chemotherapy for advanced thymoma. Preliminary results of an intergroup study. Ann Intern Med. 1990;113:520-524.
16. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy of invasive thymoma. J Clin Oncol. 1990;8:1419-1423.
17. Berruti A, Borasio P, Roncari A, Gorzegno G, Mossetti C, Dogliotti L. Neoadjuvant chemotherapy with Adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol. 1993;4:429-431.
18. Yano T, Hara N, Ichinose Y, Asoh H, Yokoyama H, Ohta M. Treatment and prognosis of primary thymic carcinoma. J Surg Oncol. 1993;52:255-258.
19. Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol. 1994;12:1164-1168.
20. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996;14:814-820.
21. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997;15:3093-3099.
22. Shin DM, Walsh GL, Komaki R, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med. 1998;129:100-104.
23. Berruti A, Borasio P, Gerbino A, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer. 199981:841-845.
24. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004;44:369-379.
25. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol. 1993;16:342-345.
26. Highley MS, Underbill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol. 1999;17:2737-2744.
27. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91:2010-2015.
28. Loehrer PJ Sr, Wang W, Johnson DH, Aisner SC, Ettinger DS. Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22:293-299.
29. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med. 2004;350:2625-2626.
30. Hsu CH, Yeh KH, Cheng AL. Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. Anticancer Res. 1997;17:1331-1334.
31. Nguyen HN, Sevin BU, Averette HE, et al. Radiosensitization of uterine cancer cell lines by cytotoxic agents. Gynecol Oncol. 1993;48:16-22.
32. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med. 2004;14:959-970.
33. Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587:194-205.
34. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
35. Lan C, Liu JM, Liu TW, et al. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am J Clin Pathol. 2005;124:97-102.
36. Liu JM, Chen LT, Li AF, et al. Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. Jpn J Clin Oncol. 2004;34:727-732.
37. Sasaki H, Ide N, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Gene expression analysis of human thymoma correlates with tumor stage. Int J Cancer. 2002;101:342-347.
38. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-3685.
39. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265-4274.
40. Chen FF, Yan JJ, Jin YT, Su IJ. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol. 1996;27:1089-1092.
41. Pan CC, Chen PC, Wang LS, Lee JY, Chiang H. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology. 2003;43:165-172.
42. Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer. 2005;103:630-636.
43. Sasaki H, Fukai I, Kiriyama M, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma. Surg Today. 2003;33:83-88.
44. Jarvinen TA, Liu ET. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated. Cytopathology. 2003;14:309-313.